About NTD Labs
NTD Labs is a Healthcare company based in Melville (United States) founded in 1976, and was acquired by Eurofins Scientific in April 2016. Prenatal screening for genetic defects is conducted via non-invasive tests. Its chief executive, as recorded, is Robert Friec. The company was acqui-hired. Its focus areas include Life Sciences, Clinical Genomics, Amplification Based and PCR. Its competitors include Natera, DermTech and BillionToOne; 3 of its 3 listed competitors have raised funding.
Company details
NTD Labs is a diagnostics company offering tests for prenatal screening for genetic defects like Downs Syndrome, trisomy of chromosomes 13 and 18. The company offers alpha fetoprotein screen to assess risk for open neural tube defects. Their proprietary first trimester protocol for detection of Downs Syndrome includes assessment of a combination of biochemical and biophysical markers (alpha-fetoprotein, free beta hCG and pregnancy associated plasma protein-A (PAPP-A), along with an ultrasound examination) which can detect Downs Syndrome with an accuracy of 93, and trisomy of chromosomes 13 and 18 with an accuracy of 95. The optional test for fetal nasal bone assessment increases the detection rate of Downs Syndrome to 96. These tests are non-invasive, since they are done with maternal blood. Additionally, NTD Labs offers an RT-PCR test for Zika virus, a biochemical test for assessment of risk for early onset preeclampsia, and a test of carrier status for cystic fibrosis. NTD Labs was acquired by Eurofins Labs in 2016.
- Headquarters Melville, United States
- Stage Acquired
- SectorsHealthcare
- Website ntdlabs.com
- Acquired by Eurofins Scientific (Apr 2016)
- Investors
- Acquired byEurofins Scientific
(Apr 2016)
Investors in NTD Labs
NTD Labs has secured backing from 1 investor. Prominent investors backing the company include Eurofins Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Laboratory testing and contract research services are provided globally. | 1987 | eurofins.com | Luxembourg, Luxembourg |
Investor details for NTD Labs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NTD Labs
1 people are tracked at NTD Labs (1 in leadership).
| Name | Role | Group |
|---|---|---|
Robert Friec | CEO | Leadership |
Complete people profiles for NTD Labs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NTD Labs
2 dated milestones of NTD Labs across 40 years, from founding to its latest funding, stage changes and deals.
- Founded NTD Labs is founded.
- Exit Acquired by Eurofins Scientific.
Competitors of NTD Labs
NTD Labs has 3 listed competitors in our database, 3 of them funded. They include Natera, DermTech and BillionToOne.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| dermtech.com | 1996 | San Diego, United States | $24.37M | 259 | Adhesive patch biopsies for skin cancer detection are provided. | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test |
Detailed competitors of NTD Labs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NTD Labs
Websites that share an audience with NTD Labs (ntdlabs.com).
Websites whose visitors overlap most with NTD Labs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| viacord.com | 92% | 100.7K | #263,080 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as NTD Labs (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NTD Labs
NTD Labs was founded in 1976.
NTD Labs is headquartered in Melville, United States. It is registered at Melville, New York, United States.
Robert Friec is the CEO of NTD Labs, as recorded in our data.
NTD Labs is a diagnostics company offering tests for prenatal screening for genetic defects like Downs Syndrome, trisomy of chromosomes 13 and 18. The company offers alpha fetoprotein screen to assess risk for open neural tube defects. Their proprietary first trimester protocol for detection of Downs Syndrome includes assessment of a combination of biochemical and biophysical markers (alpha-fetoprotein, free beta hCG and pregnancy associated plasma protein-A (PAPP-A), along with an ultrasound examination) which can detect Downs Syndrome with an accuracy of 93, and trisomy of chromosomes 13 and 18 with an accuracy of 95. The optional test for fetal nasal bone assessment increases the detection rate of Downs Syndrome to 96. These tests are non-invasive, since they are done with maternal blood. Additionally, NTD Labs offers an RT-PCR test for Zika virus, a biochemical test for assessment of risk for early onset preeclampsia, and a test of carrier status for cystic fibrosis. NTD Labs was acquired by Eurofins Labs in 2016.
NTD Labs's top competitors include Natera, DermTech and BillionToOne.
NTD Labs has 1 investor. Key investors include Eurofins Scientific.
Yes. NTD Labs was acquired by Eurofins Scientific in April 2016.